How to Get Lamzede (Velmanase Alfa-Tycv) Approved by Cigna in California: Complete Prior Authorization Guide

Answer Box: Getting Lamzede Covered by Cigna in California

Cigna requires prior authorization for Lamzede (velmanase alfa-tycv) in California. Submit via eviCore, CoverMyMeds, or Accredo's iAssist with confirmed alpha-mannosidosis diagnosis (enzyme/genetic testing), specialist letter, and clinical documentation. Standard review: 5 business days; expedited: 24 hours for urgent cases. If denied, file internal appeal within 180 days, then California Independent Medical Review (IMR) through DMHC—61% of medical necessity denials are overturned. Start today: Verify your plan is DMHC-regulated and gather diagnostic reports.

Table of Contents

  1. Before You Start: Plan Verification
  2. Coverage Requirements at a Glance
  3. Gather What You Need
  4. Submit the Prior Authorization Request
  5. Follow-Up and Timeline Expectations
  6. Common Denial Reasons and Solutions
  7. Appeals Process in California
  8. Renewal and Re-Authorization
  9. FAQ: Lamzede Coverage in California
  10. Checklist: Quick Reference

Before You Start: Plan Verification

Confirm Your Plan Type

First, determine if your Cigna plan is regulated by California's Department of Managed Health Care (DMHC). Most HMOs and many PPOs fall under DMHC, giving you access to California's Independent Medical Review (IMR) process. Check your insurance card or call Cigna at 1-800-882-4462 to confirm.

Check Lamzede's Formulary Status

Log into your myCigna account and search for "Lamzede" or "velmanase alfa-tycv" in the drug lookup tool. Lamzede typically requires prior authorization and must be filled through Accredo Specialty Pharmacy, Cigna's preferred specialty pharmacy.

Verify Medical vs. Pharmacy Benefit

Lamzede is usually covered under the pharmacy benefit managed by Express Scripts. This means your prior authorization will go through Express Scripts' eviCore system, not Cigna's medical benefit precertification process.

Coverage Requirements at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before coverage Express Scripts PA FAQ
Confirmed Diagnosis Alpha-mannosidosis via enzyme/genetic testing ICD-10: E77.1 Cigna Policy IP0563
Specialist Oversight Metabolic/genetic specialist involvement Provider letter Cigna Policy IP0563
FDA-Approved Dosing 1 mg/kg IV weekly Prescription FDA Label
Specialty Pharmacy Accredo dispensing required Prescription routing Cigna Specialty Pharmacy Guide

Gather What You Need

Diagnostic Documentation

Your specialist will need to provide:

  • Enzyme activity results: Alpha-mannosidase activity <0.54 nmol/min/mg protein in leukocytes
  • Genetic testing: MAN2B1 gene variants (if available)
  • Urine oligosaccharides: Elevated mannose-rich oligosaccharides
  • Clinical features: Documentation of non-CNS manifestations (skeletal, cardiac, pulmonary, immunologic)

Clinical Information Package

Clinician Corner: Your medical necessity letter should address each criterion in Cigna's Lamzede policy. Include baseline functional assessments (6-minute walk test, pulmonary function), infection history, and treatment goals. Reference the pivotal rhLAMAN-05 trial and emphasize that Lamzede is the only FDA-approved therapy for alpha-mannosidosis.

Essential documents include:

  • Complete diagnostic workup with enzyme/genetic confirmation
  • Specialist consultation notes
  • Baseline functional assessments
  • Prior therapy attempts and outcomes
  • Proposed monitoring plan

Submit the Prior Authorization Request

Electronic Submission Options

Option 1: eviCore (Express Scripts)

  1. Go to the eviCore portal
  2. Register as a provider
  3. Select "Pharmacy Drugs (Express Scripts Coverage)"
  4. Enter Lamzede (velmanase alfa-tycv) as requested medication
  5. Complete all clinical questions with supporting documentation

Option 2: CoverMyMeds

  1. Start an ePA at CoverMyMeds
  2. Select patient's Express Scripts/Cigna plan
  3. Enter drug: Lamzede
  4. Upload clinical documentation

Option 3: Accredo iAssist

  1. Log into MyAccredoPatients.com
  2. Use iAssist to submit electronic referral plus ePA
  3. Bundle prescription and prior authorization

Phone/Fax Backup

If electronic submission isn't feasible, call 1-800-882-4462 for Express Scripts drug prior authorization assistance.

Follow-Up and Timeline Expectations

California-Mandated Timelines

Review Type Cigna Timeline California Law
Standard 5 business days 2-3 business days
Expedited/Urgent 24 hours 24 hours

Tracking Your Request

Monitor status through:

  • Express Scripts member portal → "Prior Authorizations"
  • Call 1-800-882-4462 for updates
  • Accredo patient services if using their iAssist system

Sample Follow-Up Script

"Hi, I'm calling to check on prior authorization status for Lamzede for [patient name], member ID [number]. The request was submitted on [date] with reference number [if available]. Can you provide the current status and any additional information needed?"

Common Denial Reasons and Solutions

Denial Reason How to Overturn Supporting Evidence
Insufficient diagnostic proof Submit complete enzyme activity and genetic testing Mayo Clinic testing guidelines
Not medically necessary Emphasize progressive nature, lack of alternatives BIMDG clinical guidance
Experimental/investigational Highlight FDA approval for exact indication Cigna Policy IP0563
Site of care issues Justify infusion setting based on monitoring needs Clinical letter addressing anaphylaxis risk
From Our Advocates: We've seen multiple California cases where Cigna initially denied Lamzede as "experimental" despite FDA approval. In each instance, a comprehensive appeal package with genetic confirmation, specialist letters emphasizing the progressive nature of alpha-mannosidosis, and clear citation of FDA labeling led to approval—either during internal appeal or at IMR. The key was addressing every line of Cigna's denial letter point-by-point.

Appeals Process in California

Internal Appeal with Cigna

Timeline: File within 180 days of denial Decision: 15 business days (standard); 24-72 hours (expedited) What to include:

  • Point-by-point rebuttal of denial reasons
  • Updated specialist letter
  • Additional clinical evidence
  • Copy of Cigna's Lamzede policy with criteria mapping

California Independent Medical Review (IMR)

If Cigna upholds the denial, California residents can request IMR through the DMHC.

Success Rates:

  • Medical necessity denials: ~61% overturned
  • Experimental/investigational: ~36% overturned
  • Additional ~25% of cases are approved by plans after IMR is filed

How to File:

  1. Call DMHC Help Center: 888-466-2219
  2. Submit online at healthhelp.ca.gov
  3. Include all Cigna correspondence and clinical documentation

Timelines:

  • Standard IMR: 45 days
  • Expedited IMR: 7 days (often 72 hours for urgent cases)

Cost: Free to patients; binding on Cigna

When Counterforce Health analyzed California IMR outcomes for similar ultra-rare enzyme replacement therapies, they found that well-documented cases with confirmed genetic diagnoses and specialist support had significantly higher success rates, particularly when the appeal clearly demonstrated the progressive nature of the condition and lack of therapeutic alternatives.

Renewal and Re-Authorization

When to Start

Begin renewal process 60 days before current authorization expires. Cigna typically approves Lamzede for 12-month periods.

Required Documentation for Renewal

  • Updated clinical assessment showing stability or improvement
  • Functional testing results (6-minute walk test, pulmonary function)
  • Infection frequency and hospitalization data
  • Specialist letter confirming continued medical necessity
  • Documentation of adherence to therapy

FAQ: Lamzede Coverage in California

How long does Cigna prior authorization take for Lamzede in California? Standard review: 5 business days; expedited review: 24 hours for urgent medical necessity cases.

What if Lamzede is non-formulary on my plan? Request a formulary exception through Cigna's standard process. Emphasize that Lamzede is the only FDA-approved therapy for alpha-mannosidosis.

Can I request an expedited appeal? Yes, if your physician certifies that delay would seriously jeopardize your life, health, or ability to function. California law requires 24-hour decisions for urgent requests.

Does step therapy apply to Lamzede? Typically no, since Lamzede is the only FDA-approved disease-modifying therapy for alpha-mannosidosis.

What happens if I move to California from another state? Your new Cigna California plan may require fresh prior authorization. Start the process immediately upon enrollment.

How much does Lamzede cost without insurance? Approximately $1.46 million annually for a 70kg patient. Manufacturer support programs may be available—contact Chiesi Global Rare Diseases for assistance.

Checklist: Quick Reference

Before Submitting PA:

  • Confirm DMHC-regulated plan status
  • Verify Accredo specialty pharmacy requirement
  • Gather enzyme activity results (<0.54 nmol/min/mg protein)
  • Obtain genetic testing (MAN2B1) if available
  • Collect specialist consultation notes
  • Document baseline functional assessments

During PA Process:

  • Submit via eviCore, CoverMyMeds, or Accredo iAssist
  • Include complete diagnostic documentation
  • Request expedited review if medically urgent
  • Track status through Express Scripts portal
  • Document all reference numbers and contact dates

If Denied:

  • File internal appeal within 180 days
  • Submit point-by-point rebuttal with new evidence
  • Request California IMR if internal appeal fails
  • Contact DMHC Help Center: 888-466-2219
  • Consider Counterforce Health for appeal assistance

This guide provides general information about insurance coverage processes and should not be considered medical advice. For specific medical questions, consult your healthcare provider. For insurance-specific questions, contact Cigna directly or the California Department of Managed Health Care at 888-466-2219.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.